Achieve Life Sciences (ACHV) vs Biomerica (BMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed Biomerica (BMRA) over the past year, gaining 108.4% versus a loss of 34.4%. Over five years, ACHV leads with a -10.7% price change compared with -95.7% for BMRA. Achieve Life Sciences is the larger company by market cap ($741.3 million vs $8.7 million), about 85.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | BMRA |
|---|---|---|
| Share price | $7.19 | $1.89 |
| Market cap | $741.31M | $8.69M |
| 1-day change | -0.69% | -0.53% |
| YTD return | +44.67% | -25.00% |
| 1-year return | +108.41% | -34.38% |
| 5-year return | -10.68% | -95.74% |
| Forward P/E | — | 4.85 |
| EPS (TTM) | $-1.69 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.64 | $3.21 |
| 52-week low | $2.62 | $1.45 |
| Distance from 52-week high | -16.78% | -41.12% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +96.80% | — |
| Average volume | 1.43M | 70.88K |
| Shares outstanding | 103.10M | 4.60M |
| Employees | 28 | 50 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Achieve Life Sciences is about 85.3 times larger than Biomerica by market value ($741.31M vs $8.69M).
- ACHV has outperformed BMRA by 142.8 percentage points over the past year.
- The two companies sit in different sectors: Achieve Life Sciences in Health Care and Biomerica in Healthcare.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Healthcare · Medical Devices · 50 employees
ACHV vs BMRA FAQ
Which is bigger, Achieve Life Sciences or Biomerica?
Achieve Life Sciences (ACHV) is larger, with a market capitalization of $741.31M compared with $8.69M for Biomerica (BMRA).
Which stock has performed better over the past year, ACHV or BMRA?
ACHV returned +108.41% over the past 12 months, compared with -34.38% for BMRA (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and Biomerica in the same industry?
No. Achieve Life Sciences is in the Health Care sector, while Biomerica is in Healthcare.